Oculis Holding AG announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA. Dr. Donnenfeld presented the ?Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery ? a Phase 3, Double-Masked, Vehicle-Controlled Study?

on Sunday, April 7th. The results showed that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15 (vs. 24.0% with vehicle, p<0.0001), and 75.5% had absence of ocular pain at Day 4 (vs.

52.0% with vehicle, p<0.0001).